Pulmatrix

Massachusetts, United States · Healthcare · 2 employees

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, which enables better delivery of drugs to the lungs. The company is dedicated to improving the lives of patients with respiratory diseases and advancing the field of inhaled therapies.

Funding history

Seed — $1.0M — Apr 2026
Pre-Seed — $45K — Jul 2021
Venture - Series Unknown — $8.1M — Apr 2020
Seed — $3.7M — Dec 2018
Seed — $935K — Jun 2015

Recent signals

May 15, 2026: Acquired Pulmatrix to merge with Eos SENOLYTIX in 2026
Apr 15, 2026: Raised $1.0M in Seed
Mar 26, 2026: Acquired Pulmatrix to merge with Eos SENOLYTIX for healthspan
Oct 16, 2025: SEC 8-K (2.02): On October 16, 2025, Pulmatrix, Inc. announced their financial results for the third fiscal quarter ended September 30, 2025. This press release also included a corporate update and is detailed in Exhibit 99.1 attached to the filing. While the financial amounts are not specified in the excerpt, such disclosures typically highlight revenue, net income or loss, and other critical financial metrics that impact stakeholder perceptions. The corporate update may address strategic initiatives or operational changes that could influence future performance, although specific content is not included in this excerpt.
Jul 20, 2021: Raised $45K in Pre-Seed
Apr 24, 2020: Raised $8.1M in Venture - Series Unknown
Dec 18, 2018: Raised $3.7M in Seed
Jun 30, 2015: Raised $935K in Seed

See plans & pricing → Track Pulmatrix’s funding, hiring, and signals — with verified contacts — on Fundz.